By reducing the inflammatory and fibrotic markers brought on by hyperglycemia, combining SGLT-2 inhibitors with renin-angiotensin-aldosterone system (RAAS) blockers provide a unique strategy to slow the progression of DKD that is more successful than using either medication alone. The gene discussed is SLC5A2; the disease is Hyperglycemia.